成功取栓后经动脉阿替普酶与安慰剂对功能结局的影响:CHOICE随机临床试验
CHOICE为2b期随机双盲安慰剂对照试验,2018年12月至2021年5月在西班牙加泰罗尼亚7个卒中中心纳入121例大血管闭塞急性缺血性卒中患者,均在发病24小时内取栓且血管造影评分2b50至3。患者随机接受经动脉阿替普酶0.225 mg/kg(最大22.5 mg)输注15至30分钟(n=61)或安慰剂(n=52)。90天改良Rankin量表评分0或1的比例为阿替普酶组59.0%(36/61)vs 安慰剂组40.4%(21/52),调整风险差18.4%(95%CI 0.3%-36.4%;P=.047)。症状性颅内出血24小时内阿替普酶组0% vs 安慰剂组3.8%,90天死亡率8% vs 15%。
要点
- 大血管闭塞急性缺血性卒中成功取栓后,辅助经动脉阿替普酶0.225 mg/kg(最大22.5 mg)输注15至30分钟,90天mRS 0-1比例59.0% vs 安慰剂40.4%(调整风险差18.4%,95%CI 0.3%-36.4%;P=.047)。
- 症状性颅内出血24小时内阿替普酶组0% vs 安慰剂组3.8%(风险差-3.8%,95%CI -13.2%至2.5%)。
- 90天死亡率阿替普酶组8% vs 安慰剂组15%(风险差-7.2%,95%CI -19.2%至4.8%)。
- 研究因无法维持安慰剂供应和COVID-19疫情导致入组率不足而提前终止,作者认为结论为初步性且需重复验证。
适用人群与场景
- 发病24小时内接受机械取栓的大血管闭塞急性缺血性卒中患者,且取栓后血管造影评分(expanded Treatment in Cerebral Ischemia)为2b50至3。
诊断标准与关键阈值
- 取栓后血管造影评分(expanded Treatment in Cerebral Ischemia)2b50至3。
- 主要结局为90天改良Rankin量表评分0或1(范围0无症至6死亡)。
处置流程与药物剂量
- 经动脉阿替普酶0.225 mg/kg(最大剂量22.5 mg),输注15至30分钟。
红旗征与不能漏的情况
- 症状性颅内出血:24小时内发生率阿替普酶组0% vs 安慰剂组3.8%(风险差-3.8%,95%CI -13.2%至2.5%)。
研究设计与关键结果
- 2b期随机双盲安慰剂对照试验,7个卒中中心,121例随机(平均年龄70.6岁,SD 13.7;女性57例[47%]),113例按随机方案治疗。
- 主要终点:90天mRS 0-1比例阿替普酶组59.0%(36/61)vs 安慰剂组40.4%(21/52),调整风险差18.4%(95%CI 0.3%-36.4%;P=.047)。
- 安全性:24小时内症状性颅内出血阿替普酶组0% vs 安慰剂组3.8%(风险差-3.8%,95%CI -13.2%至2.5%);90天死亡率阿替普酶组8% vs 安慰剂组15%(风险差-7.2%,95%CI -19.2%至4.8%)。
- 研究因无法维持安慰剂供应和COVID-19疫情导致入组率不足而提前终止;1825例取栓患者中748例(41%)符合血管造影标准,121例(7%)随机。
证据类型、等级与局限
- 证据类型:2b期随机双盲安慰剂对照试验。
- 局限:研究因无法维持安慰剂供应和COVID-19疫情导致入组率不足而提前终止;作者认为这些发现应被解读为初步性且需要重复验证。
对床旁实践的改变
- 作者认为,在大血管闭塞急性缺血性卒中成功取栓后,辅助经动脉阿替普酶相比安慰剂可能提高90天优良神经功能结局;但因研究局限,这些发现应被解读为初步性且需要重复验证。
指南或共识出处
- CHOICE随机临床试验(ClinicalTrials.gov标识NCT03876119;EudraCT编号2018-002195-40)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is estimated that only 27% of patients with acute ischemic stroke and large vessel occlusion who undergo successful reperfusion after mechanical thrombectomy are disability free at 90 days. An incomplete microcirculatory reperfusion might contribute to these suboptimal clinical benefits.
OBJECTIVE: To investigate whether treatment with adjunct intra-arterial alteplase after thrombectomy improves outcomes following reperfusion.
DESIGN, SETTING, AND PARTICIPANTS: Phase 2b randomized, double-blind, placebo-controlled trial performed from December 2018 through May 2021 in 7 stroke centers in Catalonia, Spain. The study included 121 patients with large vessel occlusion acute ischemic stroke treated with thrombectomy within 24 hours after stroke onset and with an expanded Treatment in Cerebral Ischemia angiographic score of 2b50 to 3.
INTERVENTIONS: Participants were randomized to receive intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes (n = 61) or placebo (n = 52).
MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in proportion of patients achieving a score of 0 or 1 on the 90-day modified Rankin Scale (range, 0 [no symptoms] to 6 [death]) in all patients treated as randomized. Safety outcomes included rate of symptomatic intracranial hemorrhage and death.
RESULTS: The study was terminated early for inability to maintain placebo availability and enrollment rate because of the COVID-19 pandemic. Of 1825 patients with acute ischemic stroke treated with thrombectomy at the 7 study sites, 748 (41%) patients fulfilled the angiographic criteria, 121 (7%) patients were randomized (mean age, 70.6 [SD, 13.7] years; 57 women [47%]), and 113 (6%) were treated as randomized. The proportion of participants with a modified Rankin Scale score of 0 or 1 at 90 days was 59.0% (36/61) with alteplase and 40.4% (21/52) with placebo (adjusted risk difference, 18.4%; 95% CI, 0.3%-36.4%; P = .047). The proportion of patients with symptomatic intracranial hemorrhage within 24 hours was 0% with alteplase and 3.8% with placebo (risk difference, -3.8%; 95% CI, -13.2% to 2.5%). Ninety-day mortality was 8% with alteplase and 15% with placebo (risk difference, -7.2%; 95% CI, -19.2% to 4.8%).
CONCLUSIONS AND RELEVANCE: Among patients with large vessel occlusion acute ischemic stroke and successful reperfusion following thrombectomy, the use of adjunct intra-arterial alteplase compared with placebo resulted in a greater likelihood of excellent neurological outcome at 90 days. However, because of study limitations, these findings should be interpreted as preliminary and require replication.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03876119; EudraCT Number: 2018-002195-40.
参考来源
- Renú A, Millán M, San Román L, et al. Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial. JAMA. 2022. PMID: 35143603. doi:10.1001/jama.2022.1645
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。